These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

157 related items for PubMed ID: 25170840

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Therapeutic implications of the kinetics of immunomodulation during single or combined treatment of melanoma patients with dacarbazine and interferon-alpha.
    Konjević G, Jović V, Radulović S, Jelić S, Dzodić R, Spuzić I.
    Neoplasma; 2001; 48(3):175-81. PubMed ID: 11583285
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Topical CpG enhances the response of murine malignant melanoma to dacarbazine.
    Najar HM, Dutz JP.
    J Invest Dermatol; 2008 Sep; 128(9):2204-10. PubMed ID: 18368132
    [Abstract] [Full Text] [Related]

  • 5. Effective treatment of advanced human melanoma metastasis in immunodeficient mice using combination metronomic chemotherapy regimens.
    Cruz-Munoz W, Man S, Kerbel RS.
    Clin Cancer Res; 2009 Aug 01; 15(15):4867-74. PubMed ID: 19622578
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study.
    Robert C, Dummer R, Gutzmer R, Lorigan P, Kim KB, Nyakas M, Arance A, Liszkay G, Schadendorf D, Cantarini M, Spencer S, Middleton MR.
    Lancet Oncol; 2013 Jul 01; 14(8):733-40. PubMed ID: 23735514
    [Abstract] [Full Text] [Related]

  • 9. Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy: Three-Year Follow-up of a Randomized Phase 3 Trial.
    Ascierto PA, Long GV, Robert C, Brady B, Dutriaux C, Di Giacomo AM, Mortier L, Hassel JC, Rutkowski P, McNeil C, Kalinka-Warzocha E, Savage KJ, Hernberg MM, Lebbé C, Charles J, Mihalcioiu C, Chiarion-Sileni V, Mauch C, Cognetti F, Ny L, Arance A, Svane IM, Schadendorf D, Gogas H, Saci A, Jiang J, Rizzo J, Atkinson V.
    JAMA Oncol; 2019 Feb 01; 5(2):187-194. PubMed ID: 30422243
    [Abstract] [Full Text] [Related]

  • 10. Parthenolide enhances dacarbazine activity against melanoma cells.
    Koprowska K, Hartman ML, Sztiller-Sikorska M, Czyz ME.
    Anticancer Drugs; 2013 Sep 01; 24(8):835-45. PubMed ID: 23797801
    [Abstract] [Full Text] [Related]

  • 11. Effect of the lymphocyte-to-monocyte ratio on the clinical outcome of chemotherapy administration in advanced melanoma patients.
    Leontovich AA, Dronca RS, Nevala WK, Thompson MA, Kottschade LA, Ivanov LV, Markovic SN, Melanoma Study Group of the Mayo Clinic Cancer Center.
    Melanoma Res; 2017 Feb 01; 27(1):32-42. PubMed ID: 27824739
    [Abstract] [Full Text] [Related]

  • 12. Similar efficacy for phase I trials in comparison with DTIC for advanced malignant melanoma: an analysis of melanoma outcomes in CTEP-sponsored phase I trials 1995-2011.
    Luke JJ, Rubinstein LV, Smith GL, Ivy SP, Harris PJ.
    Melanoma Res; 2013 Apr 01; 23(2):152-8. PubMed ID: 23411478
    [Abstract] [Full Text] [Related]

  • 13. Serial monitoring of circulating melanoma cells during neoadjuvant biochemotherapy for stage III melanoma: outcome prediction in a multicenter trial.
    Koyanagi K, O'Day SJ, Gonzalez R, Lewis K, Robinson WA, Amatruda TT, Wang HJ, Elashoff RM, Takeuchi H, Umetani N, Hoon DS.
    J Clin Oncol; 2005 Nov 01; 23(31):8057-64. PubMed ID: 16258104
    [Abstract] [Full Text] [Related]

  • 14. [Disseminated melanoma treatment].
    Neidhardt-Bérard EM, Négrier S.
    Rev Prat; 2004 Jun 15; 54(11):1210-4. PubMed ID: 15496028
    [Abstract] [Full Text] [Related]

  • 15. Temozolomide for advanced, metastatic melanoma.
    Cohen MH, Johnson JR, Middleton MR.
    J Clin Oncol; 2000 May 15; 18(10):2185. PubMed ID: 10811684
    [No Abstract] [Full Text] [Related]

  • 16. Changes in immunological parameters after combination adjuvant therapy with intravenous DTIC, ACNU, and VCR, and local injection of IFN-beta (DAV + IFN-beta therapy) into malignant melanoma.
    Umeda T, Aoki K, Yokoyama A, Ohara H, Hayashi O, Tanaka K, Nishioka K.
    J Dermatol; 1998 Sep 15; 25(9):569-72. PubMed ID: 9798342
    [Abstract] [Full Text] [Related]

  • 17. Dacarbazine-based chemotherapy as first-line treatment in noncutaneous metastatic melanoma: multicenter, retrospective analysis in Asia.
    Yi JH, Yi SY, Lee HR, Lee SI, Lim DH, Kim JH, Park KW, Lee J.
    Melanoma Res; 2011 Jun 15; 21(3):223-7. PubMed ID: 21471822
    [Abstract] [Full Text] [Related]

  • 18. Dacarbazine-mediated upregulation of NKG2D ligands on tumor cells activates NK and CD8 T cells and restrains melanoma growth.
    Hervieu A, Rébé C, Végran F, Chalmin F, Bruchard M, Vabres P, Apetoh L, Ghiringhelli F, Mignot G.
    J Invest Dermatol; 2013 Feb 15; 133(2):499-508. PubMed ID: 22951720
    [Abstract] [Full Text] [Related]

  • 19. Chemoimmunotherapy with dacarbazine, cisplatin, interferon-alpha2b and interleukin-2 versus two cycles of dacarbazine followed by chemoimmunotherapy in patients with metastatic melanoma: a randomised phase II study of the European Organization for Research and Treatment of Cancer Melanoma Group.
    Punt CJ, Suciu S, Gore MA, Koller J, Kruit WH, Thomas J, Patel P, Lienard D, Eggermont AM, Keilholz U.
    Eur J Cancer; 2006 Nov 15; 42(17):2991-5. PubMed ID: 17023156
    [Abstract] [Full Text] [Related]

  • 20. Impact of prior treatment with immune checkpoint inhibitors on dacarbazine efficacy in metastatic melanoma.
    Bouchereau S, Chaplain L, Fort M, Beauchet A, Sidibé T, Chapalain M, Gonzalez-Lara L, Longvert C, Blom A, Saiag P, Funck-Brentano E.
    Br J Cancer; 2021 Sep 15; 125(7):948-954. PubMed ID: 34262147
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.